Drugmaker makes $37bn in vaccine sales and predicts bumper year ahead from Covid jabs and pill
Pfizer made nearly $37bn (£27bn) in sales from its Covid-19 vaccine last year – making it one of the most lucrative products in history – and has forecast another bumper year in 2022, with a big boost coming from its Covid-19 pill Paxlovid.
The US drugmaker’s overall revenues in 2021 doubled to $81.3bn, and it expects to make record revenues of $98bn to $102bn this year.
